GSK said that the data so far suggests they could be “best-in-class” new vaccines that could “change the standard of care.” “With this new agreement, we will apply GSK’s capabilities ...

Wave Life Sciences has taken a step toward validating a new modality, becoming the first group to report therapeutic RNA editing in humans. The update on the GSK-partnered prospect sent Wave’s ...

GSK (GSK) plc and Chimagen Biosciences, a privately held biotechnology company, announced an agreement for GSK to acquire CMG1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager, from ...

Questions remain about GSK’s ability to come up with new drugs and litigation over the antacid Zantac, and the stock still ...

GSK announced positive results from two phase 3 clinical trials evaluating its experimental drug, depemokimab, for chronic rhinosinusitis with nasal polyps affecting 4% of the population.

Researchers from the Center for Regenerative Medicine (CReM) at Boston University and Boston Medical Center (BMC) have announced a new collaboration with the global biopharma company GSK to ...

Shares in British pharmaceutical giant GSK rose after the company said it resolved a vast majority of lawsuits in the U.S. claiming its discontinued heartburn medicine Zantac caused cancer.

GSK plc GSK announced new data from the phase III AReSVi-006 (Adult Respiratory Syncytial Virus) study. The study evaluated the efficacy of a single dose of its respiratory syncytial virus (RSV ...

Bernstein analyst Justin Smith maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p2,610.00. The company’s shares opened today at p1,430.50.

On Wednesday, the FDA accepted GSK plc’s (NYSE:GSK) marketing application seeking approval for gepotidacin, an investigational, oral antibiotic for adult and adolescent females with ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

Also Read: GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement. Over half of all women are affected by uUTIs in their lifetime, with approximately 30% suffering from recurrent disease. New ...